BIOCON
|
|
BOM : 532523     NSE : BIOCON     | |
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Good [Stock is Cheap] Debt : High |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Downward Pledged Shares : None or < 25% |
Mar 22,2023 |
Price(EOD): ₹ 203.65
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 24,450.22 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
BIOCON | -8.2% | -10.6% | -39% |
SUN PHARMACEUTICAL INDUSTRIES | 0.5% | -1.3% | 4.6% |
DIVIS LABORATORIES | -0.4% | -3.9% | -37.8% |
CIPLA | -2.3% | -10.4% | -17.8% |
DR REDDYS LABORATORIES | 2.1% | 0.1% | 10.3% |
TORRENT PHARMACEUTICALS | -2.2% | 2.5% | 9.6% |
ABBOTT INDIA | 3.6% | 7.2% | 23.2% |
ZYDUS LIFESCIENCES | -0.3% | 3% | 30.4% |
ALKEM LABORATORIES | 2% | -1.8% | -11.2% |
FUNDAMENTAL ANALYSIS OF BIOCON
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF BIOCON
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
35.32
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 692.30 Cr
[Latest Qtr - Dec2022 - Consolidated Results ] 2.97
P/B Calculated based on Book Value of Rs 8,228.40 Cr
[Latest Year - Mar2022 - Consolidated Results ] 2.49
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 9,809.10 Cr
[Latest Qtr - Dec2022 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
-1% -58% -57% |
SHARE PRICE MOMENTUM OF BIOCON
BIOCON vs SENSEX
DEBT OF BIOCON
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2022 2021 2020 Avg_3yrs |
0.01 0 0 - |
0.6 0.58 0.4 0.53 |
[Last Annual Data : Mar2022]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF BIOCON
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Dec2022 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF BIOCON
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
26.79% 36.88% -88.31% -68.3% |
35.27% 31.97% -90.48% -86.92% |
QtrlyTrend |
0 | |
Latest Qtr: Dec2022 | ||
Quarterly Result Analysis → |
BIOCON related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE LARGE MIDCAP | 1.1% | -3.7% | -1.7% |
S&P BSE 200 | 1.1% | -3.7% | -1.7% |
S&P BSE 250 LARGEMIDCAP | 1% | -3.7% | -1.7% |
S&P BSE 500 | 1% | -3.6% | -1.7% |
S&P BSE ALLCAP | 0.9% | -3.6% | -1.7% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY NEXT 50 | 1.7% | -1.2% | -7.5% |
NIFTY 100 | 1.2% | -3.9% | -2.7% |
NIFTY 100 EQUAL WEIGHT | 1.1% | -2.7% | -4.9% |
NIFTY 200 | 1.1% | -3.7% | -1.9% |
NIFTY PHARMA | 1% | -3.3% | -13.2% |
You may also like the below Video Courses
FAQ about BIOCON
Is BIOCON good for long term investment?
As on Mar 22,2023, the Fundamentals of BIOCON look Strong and hence it may be good for long term investment! See Financial Performance of BIOCON . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is BIOCON UnderValued or OverValued?
As on Mar 22,2023, BIOCON is Under Valued based on the estimates of intrinsic value and hence may be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of BIOCON ?
As on Mar 22,2023, the Intrinsic Value of BIOCON is Rs. 476.20 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 204.84
Fair Value [Median EV / Sales Model] : Rs. 479.19
Fair Value [Median Price / Sales Model] : Rs. 476.20
Estimated Median Fair Value of BIOCON : Rs. 476.20
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.
Is BIOCON trading at a Premium or Discount?
As on Mar 22,2023, BIOCON is trading at a Discount of -57% based on the estimates of Median Intrinsic Value!